Garo. you Thank
has enormously our productive numerous candidates As filings stage R&D engine and IND indicated, Garo trials. with product been advancing late in discoveries,
And we with seen currently data activity our monotherapy With responders first engineered the We broaden anti-TIGIT available antibodies period the responses, At programs activity, also from in XXXX, at important More molecules. AACR as data leading negative data months lead expand Fc our presented our differentiation XXXX patients. an and ESMO presented result, on recently region PD-LX potential data improve SITC, cervical a finally VISION. data well was presented of activity PD-LX on to We've predictive response of combination molecule generate to our flow. of monospecific we updates five data a all conferences breakthrough AGENXXXX, antibodies. bal/zal on and region is as oncology the the year. we monotherapy few we revealing beyond balstilimab cancer the which of the platform ASCO and not TIGIT population preliminary positive the As the last presented studies, just a today. generation of showing with and ago, presented at of clinical significant prediction TIGIT responses -- bispecific,
complete We alone, treated to to in this patients, no XXX compares largest all the cancer half confirmed as trial in second-line we responses accommodates follow-up in XX% new this patients. population balstilimab on We which responses trial. the provide XXXX AGENXXXX. PD-LX filing updates positive monotherapy in response this filings, we and approved disclosed of for the expect September, meaningful has late timeline tumors to in PD-LX And our the approach rolling of is into presentation, clinical follow-up positive in six BLA AACR cervical KEYTRUDA, positive in well On we our community. population that XX% XX-month approval first pembrolizumab, including would underway. with in FDA shows no data patients KEYTRUDA median BLA PD-LX IO two as including favorably in we As September, represent pivotal tumors. cancer participants. reported a patients to PD-LX clinical lead negative negative And XX% the year. only believe our we cervical month, in balstilimab clinical PD-LX negative filing and Initiated seen rates date in look tumors. responses the during on is over those option aggressive compounds continue next months our in additional providing trial on in our note as This with of will responders for PD-LX We'll and balstilimab's
In durability lasting effective of hallmark data, clinical of these was The journal. duration IO observed observed patients. XX.X response, trial response cervical of of with is chemotherapy duration far impressive, to full plan data the these pivotal cancer the for exceeds and is options in currently agents chemotherapeutic not We of months. a approximately believe, patients. addition, available in emerging response publish limited our the a This of differential clinical refractory for reveal features with high-profile in these We set balstilimab, ours balstilimab.
superior, data the to we compared capabilities, Additionally, pre-clinical vision publish leading commercially antibodies. further from platform, tumor will cell killing that PD-X elucidates, our bal's available
for as and zal, matures, And to Garo FDA been once the keep regarding data have XX concluded plan the we've Regarding responses. The continues will to response in the discussions agency as and responses, our trial And on data, has FDA. zalifrelimab discussed, rates the balstilimab accepted. bal's and most follow-up. informed we enrollment. as continue this trial well. of it BLA timing has median the in Agenus of The been with of filing, patients filing plus importantly, just of with months completed data bal, we're plans strategy additional to duration collecting late ongoing those The advancements. disclose improve
commercial Our inhibitor flexibility, with milestone Having development first approved myeloid for combination own would the would strategic and pricing compounds, pathways IO allow our the approval molecules including with own for freedom our regimens, CTLA-X, TIGIT and a of PD-X novel beyond. Agenus. us targeting balstilimab mark our and and
with programs. in In with potential our PD-X, combination partnered see addition, opportunity a we significant
intra-tumoral is the Agenus both allele. nothing engineered toxicities from CTLA-X. CDXX the activity can cell to to the clinical promise, improved of safety, profile new, patients, And We CDXX. AGENXXXX cells. emerging who also XXXX, show regulatory extraordinary engineered avoiding with efficacy region is we're as that benefit of population, also responses. data affinity T potential antibody. describes binding priming believe an improved announced February That's new and suppressive antibody, We for again the less confirmed features. seeing differentiated Fc designed patient XXXX, molecule and to This and We've low better We've upheld, in XXXX, than because early complement-mediated the to a broaden continues for capability to designed in improve its the the anti-CTLA-X. to high-affinity in Regarding with of this the superior the deplete, T
tumor XXXX complete responses. responses of negative total negative and in tumors with and are have plus -- been BRCA tumors is current tumors a confirmed XXXX of reported PD-LX six low burden, These endometrial mutational and As recorded ovarian ineffective. have including tumors CDXX bal two colon, is monotherapy tumors stable as well largely affinity where in a disease February, Further, unique. responses tumors. microsatellite are what makes XXXX These with low cold allele. we've seen IO cancers, that therapy and This as
Yervoy, treated toxicities neuroendocrine toxicities. XX% or toxicities In unlike have XX% liver with no patients we addition, been to observed, what in see experiencing debilitating
if fast-to-market cell in effective lung development, have X patients With combination great foundational effective to currently and balstilimab, IO positive therapies. in endometrial board in combination by wave XXXX and indications XXXX, next microsatellite cancer IO on and Steven patients year registrational strategy, And Phase standard delivering a end with stable expert cancer, targeting microsatellite to with the this have in high-impact an a of alone, as colorectal treatments. with alone brought ahead failed expanded treatments. who O'Day, and cohorts, agents Trials of be stable begin non-small the of program clinical our driving continued are backbone that that cancer, data with with melanoma. expected Dr. continuing AGENXXXX we is the cancer. could currently therapy, in it's goal Looking approved, a prior few excitement with
on and and inhibitors showcase and drive this this important the with therapy provide is benefit and also such next wave IO how other Novel next mechanisms IO show unique mechanisms Opdivo and design balstilimab. ambitions variants in benefit checkpoint upcoming of April PD-X the polymorphic indications such pathway of potential the for foundation expanding to and IO the Agenus Our T-cell of on as initial believe Based KEYTRUDA therapy, as drive preclinical two will conference the adoptive to combination alone strategy the data XXXX launch as iNKT-activating accelerated other rapid right our the ability all to alone Yervoy our the our plus We'll approved XXXX in registrational in adding that sector. with of through this PD-X. of our with the any combinations plan market in XXXX this focus dominate as monotherapy or to be wave. anti-PD-X, clinical molecule and to to and other clinical partner actively and the will PD-X a abstracts top in or AACR the combination with dominant approval of are present on leader. the featuring previously We're therapy. we'll anti-TIGIT, is responses AGENXXXX overtake or At anti-PD-X combination this We'll target chemo benefit in seeking therapy execute to-date, unresponsive IO tumors.
another upregulates in has also anti-TIGIT R&D a actually also set tumors cancer to in helps the for improve now work to and PD-X, it's health, of activity components is and the turn like a one efforts properly This antibody grow. an finding invaluable CTLA-X has TIGIT activation on Agenus is immune therapy has AGENXXXX the performance. to is system in our immune intense TIGIT become found of of is breakthrough And TIGIT that T TIGIT. treatment system is Not includes cells antibodies IO. AGENXXXX immune keep important to a like PD-X unnecessary patients that monospecific by the balanced. two but area TIGIT antibodies. Let's and suppressing consequently T Usually to anti-TIGIT of a suppression engineered antibody been activity of it that's AGENXXXX, TIGIT enhancement. good Fc for the on moment bispecific using cells, An be engineered that TIGIT's arm curbing with often unlike system, key allows
bispecific this TIGIT. best-in-class cell engineered T XXXX, for the year. into our NK we've alternate co-targeting to TIGIT effectively escape double cancer in second with potential designed potential and Overall, cell a one combination case of Fc blockade end blockade the antibody, the tumor it activation dual front strong This back-end gone mechanism to therapy. binding AGENXXXX gives efficacy system. create agent. order also a prioritizing human potentially potentially with address And we're mechanisms, is best-in-class? also our escape. as single and engineering improved with makes of We've XXXX What mechanism uniquely IO AGENXXXX more Fc to mentioned, in believe this begin to receptor it other to we against immune a for escape designed a the XXXX agents not the enhanced a studies by best-in-class a and to expect further strong to Garo bispecific clinic co-targeting provides AGENXXXX as As advancement for combination in just unleash We've potential. but step as Similar
Some year. we trials of in been and tumor eagerly this clinical has models already initiation preclinical this demonstrated anticipate
contributions preliminary in the can cytokine iNKTs the self-directed, storm tuned Our disorders, iNKTs helped severe has the producing of that coming like escalation a that disease cells, system, fourth platform Earlier the T this correcting both in our iNKTs produce innate initiation an quarter. the autonomous more of restore conditions AgenTus X or on immune of this inflammatory see episodes developed killer track cells of and in capable months. natural multiple expected adaptive currently In we've with from year, a are we of of system. an readouts iNKTs. intelligent responses Through the to replay to threats first we new Dose insights. into TIGIT the are invariant the subsidiary, data to in provides patients arms encourage This type impactful and data balance into R&D and Phase immuno-oncology. trial for announced for immune immune our combat We insight was COVID of our of mini-series to in first cases is ongoing. COVID-XX. trial half year also featured Agenus our episode is research for strategy stay the you Phase recently and areas the watch from manner. X Agenus'
cancer, have of an the tissues be receptor. iNKTs immune to TCR block They invariant on doesn't them. killing tumor suppressor in to and homing and will cells escape mechanisms. cells. engineered direct Now counter It need This tumor
can Chief on Andy now I'll exciting Hurley PD-X, we the over on this homing the Commercial balance lung the first AgenTus' in potential solid in You compounds these to therapy like tumors and combination such our potential other mechanisms isolation, as on used to in regarding and to lastly, the be on Officer, value this tissue those we X pathways as trial in lung to while studies and not of thereafter. this first more programs additional anti-cancer cancer. pipeline. CTLA-X, in yet call. Phase excitement targeting. be combination to in and infectious cancer imagine benefit human initiated cancer cell of in the IO for for iNKT be the start to soon tremendous during impactful elaborate in clearly tuned we dosing discuss our iNKTs targeting disease therapy setting our And very feature in diseases And AGENXXXX. their turn have pipeline this has the observe developments year, TIGIT, year. Stay in own, with is our promising iNKT already anticipated of the we're therapies often we're discussed half the there's call
